79407-30-0

Upstream product

• 60893-68-7 methyl 4-(2-methoxyethoxy)benzoate 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 6482-24-2 2-Bromoethyl methyl ether 
• 27890-92-2 4-(2-methoxy-ethoxy)-benzoic acid 
• 36824-00-7 4-[2-(methoxy)ethoxy]-benzaldehyde 

Downstream Products

• 106341-33-7 1-(bromomethyl)-4-(2-methoxyethoxy)benzene 
• 1422064-10-5 methyl 3-{(2S)-1-[4-(2-methoxyethoxy)benzyl]-5-oxopyrrolidin-2-yl} propanoate 
• 1422064-29-6 methyl 1-[4-(2-methoxyethoxy)benzyl]-5-oxo-L-prolinate 
• 1422064-11-6 (5R)-5-(3-hydroxypropyl)-1-[4-(2-methoxyethoxy)benzyl]-pyrrolidin-2-one 
• 1422064-12-7 3-{(2R)-1-[4-(2-methoxyethoxy)benzyl]-5-oxopyrrolidin-2-yl}propyl 4-methylbenzenesulfonate 
• 1422064-13-8 (5R)-5-[3-(1H-imidazol-1-yl)propyl]-1-[4-(2-methoxyethoxy)benzyl]-pyrrolidin-2-one 
• 1422064-14-9 benzyl 1-(3-{(2R)-1-[4-(2-methoxyethoxy)benzyl]-5-oxopyrrolidin-2-yl}propyl)-1H-imidazole-5-carboxylate 
• 1422064-15-0 benzyl 1-(3-{(2R)-1-[4-(2-methoxyethoxy)benzyl]-5-oxopyrrolidin-2-yl}propyl)-1H-imidazole-4-carboxylate 
• 1422064-16-1 1-(3-{(2R)-1-[4-(2-methoxyethoxy)benzyl]-5-oxopyrrolidin-2-yl}propyl)-1H-imidazole-5-carboxylic acid 
• 1422064-17-2 1-(3-{(2R)-1-[4-(2-methoxyethoxy)benzyl]-5-oxopyrrolidin-2-yl}propyl)-1H-imidazole-4-carboxylic acid 
• 1422064-38-7 1-[4-(2-methoxyethoxy)benzyl]-5-oxo-L-prolyl-L-histidine 
• 1422064-32-1 1-[4-(2-methoxyethoxy)benzyl]-5-oxo-L-proline 
• 1422064-35-4 benzyl 1-[4-(2-methoxyethoxy)benzyl]-5-oxo-L-prolyl-3-trityl-L-histidinate 
• 79407-31-1 1-(chloromethyl)-4-(2-methoxyethoxy)benzene 

Relevant academic research and scientific papers

SUBSTITUTED INDOLES WITH INHIBITORY ACTIVITY

Disclosed are substituted indole compounds and compositions. The substituted indole compounds and compositions can be used for treating or preventing acute renal failure in a subject. The compounds and compositions can also be used for treating an infecti

[6,6] FUSED BICYCLIC HDAC8 INHIBITORS

The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2', L, X, W, Y1,Y2,

2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE

The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

New artificial fluoro-cofactor of hydride transfer with novel fluorescence assay for redox biocatalysis

A new artificial fluoro-cofactor was developed for the replacement of natural cofactors NAD(P), exhibiting a high hydride transfer ability. More importantly, we established a new and fast screening method for the evaluation of the properties of artificial cofactors based on the fluorescence assay and visible color change.

NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE

The invention relates to activators of soluble guanylate cyclase of formula (I) and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pre

Synthesis of new optically active 2-pyrrolidinones

A new class of optically active 2-pyrrolidinones was synthesized, starting from S-pyroglutamic acid, a well known natural chiral synthon. The synthetic design followed led to the insertion of various substituents at positions 1 and 5 of the 2-pyrrolidinone ring, including the imidazole moiety. Some of them possess two or three stereogenic centers, the configuration of which was retained under the mild conditions used. The new compounds also carry an imidazole moiety, which, along with the 2-pyrrolidinone template, may prove pivotal to several biological processes.

SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY

Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

Directed lithiation in arenetricarbonylchromium(0) complexes: Assessment of some directing group specificities and of electrophilic quench efficacies

The synthesis of a series of phenol ethers and 4-triisopropylsilyloxymethylphenol ethers and their η6-tricarbonylchromium(0) complexes are reported. The directed lithiation of these followed by quenching with a series of electrophiles gave acce